Stay updated with breaking news from Sam Gandy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WEDNESDAY, May 10, 2023 (HealthDay News) -- Researchers have isolated for the first time a free-floating form of amyloid beta that appears to be a key driver of Alzheimer’s disease.
The drug is made by Japan's Eisai and its U.S. partner, Biogen, which is based in Cambridge. Read more at Boston.com.
A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. It’s a
Leqembi can slow early progression by months but has safety concerns. Most patients will likely have to wait months to get the IV drug, which will cost about $26,500 a year. Insurers need to decide whether and how much to cover it. Medicare isn’t expected to pay for it until later this year.
United States health officials last week approved a new Alzheimer’s drug. The drug, called Leqembi, is the first to slow the decline in memory by several months.